NCT03071861View on ClinicalTrials.gov

Mild Encephalopathy in the Newborn Treated With Darbepoetin

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

December 1, 2019

Study Completion Date

September 1, 2022

Conditions
Neonatal EncephalopathyHypoxic-Ischemic Encephalopathy Mild
Interventions
DRUG

Darbepoetin Alfa

Single dose of 10 mcg/kg Darbepoetin Alpha given IV at less than 24 hours of age

DRUG

Normal Saline

Single dose of normal saline, IV, given at less than 24 hours of age

Trial Locations (1)

84108

University of Utah, Salt Lake City

All Listed Sponsors
collaborator

University of Utah

OTHER

lead

University of New Mexico

OTHER

NCT03071861 - Mild Encephalopathy in the Newborn Treated With Darbepoetin | Biotech Hunter | Biotech Hunter